Filter By Category
Archives
Share on -
ADAVIVINT
Generic Name: ADAVIVINT
ABSTRACT -
Adavivint, also known as lorecivivint or SM04690, is an investigational small-molecule inhibitor of signaling pathways involved in Wnt modulation, with reported activity through CLK2 and DYRK1A inhibition. It has been developed as an intra-articular therapy for knee osteoarthritis and studied for potential disease-modifying effects on inflammation, cartilage catabolism, and joint structure. It is not a routine approved therapy unless approved by a local regulator.
DOSAGE -
Adavivint is investigational and does not have a universally established approved dosage regimen.
- It has been studied as an intra-articular injection into the target knee under clinical-trial conditions.
- Clinical programs have evaluated single-injection, every-six-month, or once-yearly protocol-defined regimens depending on trial design.
- The dose, injection technique, eligibility criteria, and follow-up schedule must be determined by the protocol or treating specialist.
- It should not be self-administered or used outside specialist supervision.
SIDE EFFECTS -
Reported or potential side effects may include:
- Injection-site pain
- Joint pain or swelling
- Arthralgia
- Headache
- Upper respiratory tract symptoms
- Back pain
- Nausea
- Transient knee discomfort
- Rash or itching
- Laboratory abnormalities if monitored
- Infection risk related to joint injection procedure
- Allergic or hypersensitivity reactions
ALLRGIC REACTIONS–
(These symptoms may indicate an allergic reaction to the drug.)
- Skin rash
- Itching
- Hives
- Swelling of face, lips, tongue, or throat
- Difficulty breathing
- Wheezing
- Severe dizziness
- Rapid heartbeat
- Chest tightness
- Anaphylaxis
- Severe hypersensitivity reactions
DRUG INTERACTIONS–
The full drug-interaction profile has not been completely established. Use caution with:
- Intra-articular corticosteroids, hyaluronic acid, or other knee injections close to dosing
- Anticoagulants or antiplatelet medicines that may increase injection-site bleeding risk
- Other investigational osteoarthritis disease-modifying therapies
- Immunosuppressants or infection-risk medicines when joint injection is planned
- Other investigational medicines or therapies used in the same protocol
- Medicines that increase the risk of overlapping organ toxicity
- Immunosuppressive, anticancer, antiviral, cardiovascular, or neurologic medicines when clinically relevant
- Herbal products and supplements with uncertain pharmacologic effects
PREAUTIONS–
- Assess knee diagnosis, radiographic severity, infection risk, bleeding risk, and recent joint procedures before injection.
- Do not inject into an actively infected joint or overlying skin infection.
- Monitor for post-injection pain, swelling, fever, or signs of septic arthritis.
- Use only in settings where qualified healthcare professionals can assess eligibility, monitor response, and manage adverse reactions.
- Review baseline medical history, organ function, concomitant medicines, pregnancy status, and allergy history before use.
- Monitor clinical symptoms and laboratory values as directed by the clinical protocol or treating specialist.
- Use caution in patients with severe hepatic, renal, cardiovascular, infectious, immune, or neurologic disease unless specifically allowed by protocol.
- Use during pregnancy or breastfeeding only if the potential benefit justifies the potential risk and as directed by a physician.
- Safety and effectiveness in pediatric patients may not be established unless specifically studied.
WARNINGS –
- Severe joint pain, rapidly increasing swelling, fever, redness, or inability to bear weight after injection requires urgent evaluation for joint infection or inflammatory reaction.
- This medicine is investigational or has limited publicly established clinical-use information; safety, efficacy, optimal dose, and routine clinical role may not be fully established.
- It should not be used for self-medication or substituted for an approved therapy unless directed by a qualified specialist or clinical-trial investigator.
- Treatment should be discontinued and urgent medical care sought if severe allergic reaction, severe adverse reaction, or clinical deterioration is suspected.
- Use only under medical supervision in an appropriate specialist or clinical-trial setting.
- Keep out of reach of children.
- In case of overdose or severe adverse reaction, seek immediate emergency medical attention.
Share on -
. Developed by